Loyal's STAY Study: Clinical Trial Aims to Extend Healthy Lifespan in Senior Dogs

Key Insights

• Loyal's STAY study is a nationwide clinical trial assessing a novel drug's ability to extend healthy lifespan in senior dogs, potentially delaying age-related metabolic dysfunction.
• The double-blind, placebo-controlled trial involves 1,000 dogs and requires daily oral administration of the drug, with all costs covered by Loyal.
• Participating dogs must be at least 10 years old, weigh over 14 pounds, and live near a participating veterinary clinic, excluding those with serious conditions like cancer or severe heart disease.

A clinical trial is underway across the United States to evaluate a drug developed by the biotech company Loyal, which aims to extend the healthy lifespan of senior dogs. The study, known as the STAY study, is enrolling 1,000 dogs to determine if the investigational medication can effectively delay metabolic dysfunction associated with aging, potentially leading to a longer and healthier life for canine companions.

The STAY study is a four-year, double-blind, placebo-controlled trial. Participating dogs receive a daily oral dose of either the active drug or a placebo. Neither the owners nor the veterinarians know which treatment the dog is receiving, ensuring objectivity in assessing the drug's effects. The trial covers all costs associated with participation, removing financial barriers for eligible pet owners.

Eligibility and Exclusion Criteria

To be eligible for the STAY study, dogs must be at least 10 years old, weigh 14 pounds or more, and reside near a participating veterinary clinic. Dogs with pre-existing conditions such as cancer, severe heart issues, or diabetes are excluded from participation to ensure the study focuses on the drug's impact on age-related decline rather than disease-specific complications.

Mechanism of Action

The drug being tested in the STAY study is designed to interrupt the metabolic pathways that contribute to aging in dogs. By slowing down these pathways, the drug aims to improve metabolic function, potentially extending the period of healthy activity and overall lifespan. Dr. Douglas Stramel, a participating veterinarian, explained that the drug targets metabolic dysfunction, allowing the metabolism to work better and longer.

Owner Observations and Future Implications

While the double-blind nature of the study prevents definitive conclusions at this stage, some owners have reported positive changes in their dogs' energy levels since starting the trial. Kenny Coomes, owner of Bella, a 13-year-old Labrador participating in the study, noted that Bella seems to have more energy. The results of the STAY study could pave the way for the first FDA-approved drug to specifically target aging in dogs, potentially transforming veterinary care and extending the companionship between humans and their beloved pets. More information on Loyal’s clinical trial can be found at loyal.com/clinical-trials.